Cardinal Health (NYSE:CAH) Misses Q2 Revenue Estimates

Cardinal Health (CAH) reported mixed Q2 CY2025 results, with revenue of $60.16 billion flat year-over-year and missing analyst estimates, while adjusted EPS of $2.08 surpassed expectations. Adjusted EBITDA of $743 million, however, significantly missed consensus forecasts. Despite the operational misses in the quarter, the company provided robust adjusted EPS guidance of $9.40 at the midpoint for fiscal year 2026, exceeding analyst projections and signaling a more positive forward outlook.

Analysis

Cardinal Health reported mixed Q2 CY2025 results, characterized by a conflict between current operational performance and a strong forward outlook. While adjusted EPS of $2.08 beat consensus by 2.4%, this was overshadowed by weaker top-line and core profitability metrics. Revenue of $60.16 billion was flat year-on-year and missed estimates by 1%, continuing a recent trend of slowing growth compared to its 7.8% five-year annualized rate. More critically, Adjusted EBITDA of $743 million missed expectations by a significant 10.7%, and the Free Cash Flow Margin compressed to 2.2% from 3.2% in the prior-year quarter, signaling potential pressure on operational efficiency and cash generation. The key bullish catalyst, however, is the company's guidance for the upcoming fiscal year 2026, which projects adjusted EPS of $9.40 at the midpoint, beating analyst estimates by 1.6%. This optimistic forecast, coupled with analyst expectations for an 11.8% revenue growth rebound over the next year, suggests management anticipates a significant performance improvement despite the lackluster quarter.

Key Decisions for Investors

• Investors should scrutinize the drivers behind the strong FY2026 EPS guidance, particularly how management plans to overcome the significant Adjusted EBITDA shortfall and margin pressure seen in the current quarter.
• Given the disconnect between weak current results and a positive outlook, it is crucial to monitor for tangible evidence of the forecasted 11.8% revenue re-acceleration in subsequent quarters before increasing a position.
• Consider holding existing positions while awaiting confirmation of the operational turnaround, as the stock's performance will likely hinge on its ability to bridge the gap between current performance and its ambitious future guidance.